According to the American Cancer Society, about 80–85% of all lung carcinomas fall into the non-small cell category. NSCLC doesn’t tend to spread as fast as SCLC and has a better survival rate.

Ten additional patients died from causes unrelated to lung cancer. Survival for patients with tumors ≤ 2.0 cm was 77.2% (95% CI, 68.6 to 85.8%), and survival for patients with tumors > 2.0 cm ...

The addition of serplulimab to carboplatin and nab-paclitaxel significantly prolonged survival vs chemotherapy ... or metastatic squamous non–small cell lung cancer. Pembrolizumab plus ...

Although the survival rates of other types of tumors such as breast, colon and prostate cancer have improved in the last 20 years, lung cancer ... into the squamous cell population.

Stage 4 lung cancer is the most advanced type of lung cancer. Support groups, clinical trials, and a palliative care specialist can all help you navigate this advanced stage. Lung cancer is the ...

This overview provides a thorough review of current treatment approaches for first-line management of nononcogenic addicted non–small cell lung cancer. We also address pertinent clinical ...

Significant Disease-Free Survival for Patients Diagnosed With Non-Small Cell Lung Cancer, Clinical Trial Finds Feb. 1, 2023 — New data from a clinical trial shows improved rates of survival and ...

A new meta-analysis on neoadjuvant therapy for non–small cell lung cancer (NSCLC ... Pooled overall survival demonstrated an HR of 0.65 (95% CI, 0.54-0.79; I 2 = 0%), indicating a significant ...

The oncolytic virus, MEM-288 will be studied in combination with Opdivo for patients with non-small cell lung cancer that ...

The U.S. Food and Drug Administration has approved Genentech's Alecensa (alectinib) as adjuvant treatment following tumor ...

A new study identified a set of 140 genes that may help predict enhanced disease-free survival in patients with non-small cell lung cancer (NSCLC) treated with a combination of immunotherapy and ...

Jacobio Pharma is making a play for the Chinese KRAS market, unveiling registrational lung cancer data that suggest its asset ...